DBV Technologies to Join H.C. Wainwright BioConnect Conference

DBV Technologies has announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq, scheduled for May 19, 2026, in New York. Daniel Tassé, CEO of DBV Technologies, will speak at a fireside chat on the same day at 9:00 am ET. The session will be available via live webcast and can be replayed on the company's website for 90 days post-event.

DBV Technologies, a late-stage biopharmaceutical firm, focuses on treatments for food allergies through its VIASKIN® patch technology. This technology seeks to desensitize the immune system to allergens by introducing microgram amounts of active compounds through the skin. Their programs include clinical trials for the VIASKIN Peanut Patch aimed at peanut allergies in young children.